Cogent Biosciences, Inc. COGT Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -85.7%-1.7pp | -73.7%+25.8pp | -95.4%-16.9pp | -107.6%-44.6pp | -84%-18.3pp | |
| Return on assets | -59.7%+11.2pp | -52%+27.8pp | -72.7%-7.2pp | -80.6%-25.4pp | -70.9%-13.5pp | |
| Return on invested capital | -147.2%+25.0pp | -129.2%+9.1pp | -130%-19.4pp | -153.2%-46.0pp | -172.1%-24.3pp | |
| Liquidity | ||||||
| Current ratio | 15.1×+10.0× | 14.2×+8.9× | 6.4×-0.1× | 4.2×-5.1× | 5.1×-6.9× | |
| Quick ratio | 15.1×+10.0× | 14.2×+8.9× | 6.4×-0.1× | 4.2×-5.1× | 5.1×-6.9× | |
| Cash ratio | 4.2×+1.6× | 4.9×+3.1× | 2×+0.2× | 2.2×0.0× | 2.6×-3.3× | |
| Leverage | ||||||
| Debt-to-equity | 0×-0.1× | 0×0.0× | 0.2×+0.1× | 0.4×+0.3× | 0.1×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0.1×+0.1× | 0.2×+0.2× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $3.75+93.9% | $4.94+100% | $2.20-23.0% | $1.35-64.0% | $1.93-56.6% | |
| Valuation | ||||||
| Market capitalization | $6.25B+816% | $5.45B+533% | $2.01B+69.7% | $824.32M-10.6% | $681.96M+6.1% | |
| Enterprise value | $6.02B+951% | $5.16B+560% | $1.94B+76.0% | $757.38M-11.1% | $573.05M+28.7% | |
| Price / book | 10.3×+7.2× | 8.6×+5.2× | 6.6×+2.9× | 5.3×+2.8× | 3.1×+1.6× | |
| Free cash flow yield | -4.6%+28.1pp | -4.9%+19.3pp | -12.3%+4.0pp | -28.5%-9.2pp | -32.7%-6.5pp | |
| Earnings yield | -5.7%+33.8pp | -6%+23.7pp | -14.7%+5.8pp | -34.5%-9.8pp | -39.5%-6.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Cogent Biosciences, Inc.'s ratios come from?
- Every ratio is computed from Cogent Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
